Halperin, SA, et al.
The changing and dynamic epidemiology of meningococcal disease. Vaccine
2012; 30S: B26–36.
Patel, MS. Australia's century of meningococcal disease: development and changing ecology of an accidental pathogen. Medical Journal of Australia
2007; 186: 136–141.
Australian Meningococcal Surveillance Programme. Annual report of the Australian meningococcal surveillance programme, 2002. Communicable Diseases Intelligence
2003; 27: 196–208.
Brotherton, J, et al.
Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Communicable Diseases Intelligence
2004; 28 (Suppl. 2): vii–S116.
Chiappini, E, et al.
Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatica
2010; 99: 1609–1614.
Campbell, H, et al.
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine
2009; 27S: B20–B29.
Garrido-Estepa, M, et al.
Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine
2014; 32: 2604–2609.
De Wals, P, et al.
Effectiveness of serogroup C meningococcal conjugate vaccine – a 7-year follow-up in Quebec, Canada. Pediatric Infectious Disease Journal
2011; 30: 566–569.
Cohen, NJ. Introduction of the National Meningococcal C Vaccination Program. Communicable Diseases Intelligence
2003; 27: 161–2.
De Voer, RM, et al.
Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS ONE
2010; 5: e12144.
Kinlin, LM, et al.
Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006. Vaccine
2009; 27: 1735–1740.
MacNeil, JR, Cohn, A, Zell, E. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatric Infectious Disease Journal
2011; 30: 451–455.
Richmond, P, et al.
Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infection and Immunity
2001; 69: 2378–2382.
Borrow, R, et al.
Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine
2013; 38: 4477–4486.
De Voer, RM, et al.
Age-related immunity to meningoccoal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in avidity of IgG. PLoS ONE
2011; 6: e23497.
Booy, R, et al.
Five-year antibody persistence and safety following a single dose of combined Haemophilus Influenzea type B-Neisseria meningitidis serogroup C-tetantus toxoid conjugate vaccine in Hib-primed toddlers. Pediatric Infectious Disease Journal
2015; 34: 1379–1384.
Snape, MD, et al.
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: an observational study. British Medical Journal
2008; 7659; 1487–1491.
De Whalley, PC, et al.
Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Archives of Disease in Childhood
2013; 98: 686–691.
Trotter, CL, Ramsay, ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiology Reviews
2007; 31: 101–107.
Khatami, A, et al.
Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clinical and Vaccine Immunology
2011; 18: 2038–2042.
Kaaijk, P, et al.
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? The experience of the Netherlands. BMC Infectious Diseases
2012; 12: e35, 1–6.
Donovan, H, Bedford, H. Immunisation: changes in the UK for children and young people. Nursing Children and Young People
2013; 25: 16–20.
O'Ryan, M, et al.
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs
2014; 74: 15–30.
Hull, BP, et al.
Immunisation coverage in Australia corrected for under-reporting to the Australian Childhood Immunisation Register. Australian and New Zealand Journal of Public Health
2003; 27: 533–538.
Lawrence, GL, et al.
Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia. Australian & New Zealand Journal of Public Health
2003; 27: 413–418.
Chiu, C, et al.
Vaccine preventable diseases and vaccination coverage in Australia, 2005 to 2007. Communicable Diseases Intelligence
2010; 34: Si–167.
Miller, E, et al.
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases
2011; 11: 760–768.
Shaw, KA, et al.
Meningococcal vaccine failure in conjunction with an unusual meningococcal cluster in southern Tasmania. Communicable Diseases Intelligence
2005; 29: 159–63.
Rashid, H, Booy, R. Passive smoking, invasive meningococcal disease and preventive measures: a commentary. BMC Medicine
2012; 10: 160.
Trotter, CL, et al.
No evidence of capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infectious Diseases
2006; 6: 616–617.
Campbell, H, et al.
Updated post-licensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modelling predictions of the duration of immunity. Clinical and Vaccine Immunology
2010; 17: 840–847.
Passmore, E, Ferson, MJ, Tobin, S. Meningococcal disease in NSW, 1991–2011: trends in relation to meningococcal C vaccination. NSW Public Health Bulletin
2013; 24: 119–124.
Maiden, MC, Stuart, JM, UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet
2002; 359: 1829–1831.
Tully, J, et al.
Risk and protective factors for meningococcal disease in adolescents: matched cohort study. British Medical Journal
2006; 332: 445–450.